Clinical Applications of 18F-FDG PET/CT in Monitoring Anti-Cancer Therapies.

This article reviews the current status of monitoring anti-cancer therapies, including the evolution of evaluation criteria from the World Health Organization to the Response Evaluation Criteria in Solid Tumor and the PET Response Criteria in Solid Tumor. The advantages of 18F-FDG PET/CT for response evaluation are analyzed in various malignant tumors, and the pertinent weaknesses are discussed. Finally, several future directions in monitoring anti-cancer therapies are prospected. PMID: 24372234 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24372234?dopt=Abstract

Source: Current Pharmaceutical Biotechnology - December 25, 2013 Category: Biotechnology Authors: Wu P, Zhang Y, Sun Y, Shi X, Li F, Zhu Z Tags: Curr Pharm Biotechnol Source Type: research